References
- Australia, New Zealand Multiple Sclerosis Genetics C. 2009. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 41(7):824–28.
- Barbosa JA, Mentzer SJ, Kamarck ME, Hart J, Biro PA, Strominger JL, Burakoff SJ. 1986. Gene mapping and somatic cell hybrid analysis of the role of human lymphocyte function-associated antigen-3 (LFA-3) in CTL-target cell interactions. J Immunol. 136(8):3085–91.
- Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz DA, Atkinson MA. 2005. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes. 54(5):1407–14.
- Coustet B, Agarwal SK, Gourh P, Guedj M, Mayes MD, Dieude P, Wipff J, Avouac J, Hachulla E, Diot E, et al. 2011. Association study of ITGAM, ITGAX, and CD58 autoimmune risk loci in systemic sclerosis: results from 2 large European Caucasian cohorts. J Rheumatol. 38(6):1033–38.
- Davis SJ, van der Merwe PA. 1996. The structure and ligand interactions of CD2: implications for T-cell function. Immunol Today. 17(4):177–87.
- De Jager PL, Baecher-Allan C, Maier LM, Arthur AT, Ottoboni L, Barcellos L, McCauley JL, Sawcer S, Goris A, Saarela J, et al. 2009. The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A. 106(13):5264–69.
- El Menshawy N, Eissa M, Abdeen HM, Elkhamisy EM, Joseph N. 2018. CD58; leucocyte function adhesion-3 (LFA-3) could be used as a differentiating marker between immune and non-immune thyroid disorders. Comp Clin Path. 27(3):721–27.
- Haas J, Hug A, Viehover A, Fritzsching B, Falk CS, Filser A, Vetter T, Milkova L, Korporal M, Fritz B, et al. 2005. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol. 35(11):3343–52.
- Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, de Bakker PI, Gabriel SB, Mirel DB, Ivinson AJ, et al. 2007. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 357:851–62.
- Hong J, Li N, Zhang X, Zheng B, Zhang JZ. 2005. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci U S A. 102(18):6449–54.
- Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, Chou YK, Bourdette D, Ziegler SF, Offner H, Vandenbark AA. 2005. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res. 81(1):45–52.
- Inoue N, Watanabe M, Morita M, Tomizawa R, Akamizu T, Tatsumi K, Hidaka Y, Iwatani Y. 2010. Association of functional polymorphisms related to the transcriptional level of FOXP3 with prognosis of autoimmune thyroid diseases. Clin Exp Immunol. 162(3):402–06.
- Janeway CA Jr., Bottomly K. 1994. Signals and signs for lymphocyte responses. Cell. 76(2):275–85.
- Jenkins MK. 1994. The ups and downs of T cell costimulation. Immunity. 1(6):443–46.
- Kim JY, Bae JS, Kim HJ, Shin HD. 2014. CD58 polymorphisms associated with the risk of neuromyelitis optica in a Korean population. BMC Neurol. 14:57.
- Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. 2005. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes. 54(1):92–99.
- Liu J, Shi Z, Lian Z, Chen H, Zhang Q, Feng H, Miao X, Du Q, Zhou H. 2017. Association of CD58 gene polymorphisms with NMO spectrum disorders in a Han Chinese population. J Neuroimmunol. 309:23–30.
- Menconi F, Marcocci C, Marino M. 2014. Diagnosis and classification of Graves’ disease. Autoimmun Rev. 13:398–402.
- Nakano A, Watanabe M, Iida T, Kuroda S, Matsuzuka F, Miyauchi A, Iwatani Y. 2007. Apoptosis-induced decrease of intrathyroidal CD4(+)CD25(+) regulatory T cells in autoimmune thyroid diseases. Thyroid. 17(1):25–31.
- Norcross MA. 1984. A synaptic basis for T-lymphocyte activation. Ann Immunol (Paris). 135D(2):113–34.
- Rubio JP, Stankovich J, Field J, Tubridy N, Marriott M, Chapman C, Bahlo M, Perera D, Johnson LJ, Tait BD, et al. 2008. Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians. Genes Immun. 9(7):624–30.
- Saitoh O, Nagayama Y. 2006. Regulation of Graves’ hyperthyroidism with naturally occurring CD4+CD25+ regulatory T cells in a mouse model. Endocrinology. 147(5):2417–22.
- Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 155(3):1151–64.
- Selvaraj P, Plunkett ML, Dustin M, Sanders ME, Shaw S, Springer TA. 1987. The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. Nature. 326(6111):400–03.
- Smith TR, Verdeil G, Marquardt K, Sherman LA. 2014. Contribution of TCR signaling strength to CD8+ T cell peripheral tolerance mechanisms. J Immunol. 193(7):3409–16.
- Torbati S, Karami F, Ghaffarpour M, Zamani M. 2015. Association of CD58 polymorphism with multiple sclerosis and response to interferon ss therapy in a subset of Iranian population. Cell J. 16(4):506–13.
- Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. 2004. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 199(7):971–79.
- Wakkach A, Cottrez F, Groux H. 2001. Differentiation of regulatory T cells 1 is induced by CD2 costimulation. J Immunol. 167(6):3107–13.
- Wang JH, Smolyar A, Tan K, Liu JH, Kim M, Sun ZY, Wagner G, Reinherz EL. 1999. Structure of a heterophilic adhesion complex between the human CD2 and CD58 (LFA-3) counterreceptors. Cell. 97(6):791–803.
- Weetman AP. 2013. The immunopathogenesis of chronic autoimmune thyroiditis one century after hashimoto. Eur Thyroid J. 1(4):243–50.